The Osimert 80 mg refers specifically to the Osimert product containing osimertinib 80 mg.
Everest Pharmaceuticals’ official product catalogue lists Osimert as Osimertinib INN 80 mg.
Product identity
| Product detail | Information |
| Product name | Osimert |
| Active ingredient | Osimertinib |
| Strength | 80 mg |
| Dosage form | Tablet |
| Route | Oral |
| Drug class | EGFR tyrosine kinase inhibitor |
| Therapeutic area | Oncology |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Reference product | Tagrisso |
| Originator company | AstraZeneca |
Therapeutic role
Osimertinib is used in selected EGFR-mutated NSCLC treatment settings. The exact indication depends on molecular findings, disease stage, treatment history and local regulatory labeling.
Product versus active ingredient
Osimert is the product name.
Osimertinib is the active pharmaceutical ingredient.
These terms should not be treated as interchangeable when discussing manufacturer, product packaging or regulatory identity.
Product versus reference product
Tagrisso is the AstraZeneca product through which osimertinib was originally developed and introduced. Osimert is a separate product associated with Everest Pharmaceuticals.
Safety
The medicine carries important risks including ILD/pneumonitis, QTc prolongation, cardiomyopathy, keratitis, serious skin reactions and embryo-fetal toxicity.
Verification
Everest Pharmaceuticals provides an official product-code verification facility.